WallStSmart

Amphastar P (AMPH)vsTeva Pharma Industries Ltd ADR (TEVA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 2210% more annual revenue ($17.23B vs $745.79M). AMPH leads profitability with a 13.3% profit margin vs 2.9%. TEVA appears more attractively valued with a PEG of 1.04. AMPH earns a higher WallStSmart Score of 65/100 (C+).

AMPH

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 6.0Quality: 7.0
Piotroski: 3/9Altman Z: 2.23

TEVA

Hold

42

out of 100

Grade: D

Growth: 2.7Profit: 6.0Value: 4.3Quality: 3.5
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMPHUndervalued (+28.3%)

Margin of Safety

+28.3%

Fair Value

$39.87

Current Price

$29.37

$10.50 discount

UndervaluedFair: $39.87Overvalued

Intrinsic value data unavailable for TEVA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMPH3 strengths · Avg: 8.7/10
EPS GrowthGrowth
135.1%10/10

Earnings expanding 135.1% YoY

P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

TEVA2 strengths · Avg: 8.5/10
Market CapQuality
$50.14B9/10

Large-cap with strong market position

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Areas to Watch

AMPH3 concerns · Avg: 2.7/10
Market CapQuality
$1.22B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.772/10

Expensive relative to growth rate

TEVA4 concerns · Avg: 2.5/10
Return on EquityProfitability
6.3%3/10

ROE of 6.3% — below average capital efficiency

Profit MarginProfitability
2.9%3/10

2.9% margin — thin

P/E RatioValuation
99.9x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMPH

The strongest argument for AMPH centers on EPS Growth, P/E Ratio, Price/Book.

Bull Case : TEVA

The strongest argument for TEVA centers on Market Cap, Operating Margin. PEG of 1.04 suggests the stock is reasonably priced for its growth.

Bear Case : AMPH

The primary concerns for AMPH are Market Cap, Piotroski F-Score, PEG Ratio.

Bear Case : TEVA

The primary concerns for TEVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 99.9x leaves little room for execution misses. Debt-to-equity of 2.13 is elevated, increasing financial risk.

Key Dynamics to Monitor

AMPH carries more volatility with a beta of 0.94 — expect wider price swings.

AMPH is growing revenue faster at 8.2% — sustainability is the question.

TEVA generates stronger free cash flow (121M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMPH scores higher overall (65/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphastar P

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?